DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Pivot X, Bondarenko IM, Nowecki Z. et al.
One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment.
Ann Oncol 2017;
28 (Suppl. 05) v43-v67 153PD
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.